Cytogen KRX:217330KOSDAQ
싸이토젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked7since Sep 11
In Q3 2026, Cytogen reported revenue of ₩7.7bn, up 0.9% year on year, and an operating loss of ₩1.4bn. Cytogen (싸이토젠) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Supply contract 4 quarters of losses Screener
Cytogen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩7.7bn | +0.9% | −₩1.4bn margin −17.6% | −₩2.9bn |
| Q2 2026 | ₩6.8bn | +8.7% | −₩1.2bn margin −17.8% | −₩2.2bn |
| Q1 2026 | ₩6.4bn | +14.0% | −₩1.5bn margin −23.1% | −₩1.3bn |
| Q4 2025 derived | ₩6.5bn | +17.2% | −₩2.6bn margin −39.1% | −₩5.5bn |
| Q3 2025 | ₩7.6bn | +128.5% | −₩1.3bn margin −17.2% | −₩1.6bn |
| Q2 2025 | ₩6.3bn | +426.6% | −₩1.9bn margin −30.7% | −₩2.8bn |
| Q1 2025 | ₩5.6bn | +605.8% | −₩2.4bn margin −42.3% | −₩2.4bn |
| Q4 2024 derived | ₩5.6bn | +548.0% | −₩1.9bn margin −33.8% | −₩8.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Cytogen top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Cytogen news Korean headlines
-
싸이토젠, 국가 R&D 과제 2건 동시 선정…CTC 기반 ‘진단→치료’ 밸류체인 확장
2 more on this story · 2 outlets
- 싸이토젠 “국가 혁신형 R&D 과제 2건 동시 선정”서울경제 · Sep 15 09:41
- 싸이토젠, CTC 기반 국가 R&D 2건 선정… 치료·혈액정화로 영역 확장머니투데이 · Sep 15 10:34